Analysis of immune responses in hepatocellular carcinoma patients vaccinated with alpha-fetoprotein-derived peptides
AASLD LiverLearning®, Eishiro Mizukoshi, 144130
CXCR3-high/CD81-low B cells in Early Acute HCV Infection Correlates with Severity of Liver Inflammation
AASLD LiverLearning®, Mengfei Liu, 144386
Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
AASLD LiverLearning®, Josep M Llovet, 144131
Hepatitis C non-structural proteins 5 & 5B upregulate MHC class I to evade NK cytotoxicity
AASLD LiverLearning®, Thomas Pembroke, 144387
Serum Dickkopf-1 as a novel biomarker for hepatocellular carcinoma with stem cell features
AASLD LiverLearning®, Hajime Sunagozaka, 144132
HCV-HIV Co-Infected Female Patients Do Not Exhibit Immunological Deterioration & Liver Disease Progression With HAART Therapy: A 5 Years Retrospective Observational Study
AASLD LiverLearning®, Shady Guirguis, 144388
BAFF, BAFF promoter and BAFF receptor allelic variants in HCV-related Mixed Cryoglobulinemia and Non Hodgkin’s Lymphoma.
AASLD LiverLearning®, Giorgia Ceccotti, 144389
Usefulness of modified Japan Integrated Staging (JIS) score using albumin-bilirubin (ALBI) grade as a prognostic scoring system for hepatocellular carcinoma: analysis with 2584 Japanese patients
AASLD LiverLearning®, Hirofumi Izumoto, 144146
Live cell imaging of hepatocyte cytosolic NADH/NAD+ ratio in mouse liver slices
AASLD LiverLearning®, Ricard Masia, 144402
Growth Hormone and Hepatocellular Carcinoma
AASLD LiverLearning®, Manal Hassan, 144147
TRAIL deficiency protects against fibrosis in murine nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Petra Hirsova, 144403
Cost-effectiveness of a risk-stratified hepatocellular carcinoma surveillance strategy in patients with cirrhosis
AASLD LiverLearning®, Yujin Hoshida, 144148
Hepatic Vagus Nerve Regulates Inflammatory Response of Kupffer Cell via α7 Nicotinic Acetylcholine Receptor in Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Takahiro Nishio, 144404
Quantitative molecular magnetic resonance imaging of fibrogenesis and fat content in the liver during non-alcoholic steatohepatitis
AASLD LiverLearning®, Bryan Fuchs, 144405
Translating the ABC-02 trial into daily practice: Outcome of palliative treatment in patients with advanced biliary tract cancer treated with gemcitabine and cisplatin
AASLD LiverLearning®, Jeroen van Vugt, 144162
Non-alcoholic fatty liver disease derails antiviral immunity in murine viral hepatitis
AASLD LiverLearning®, Ting Wu, 144418
The efficacy and safety of doxorubicin-eluting bead transarterial chemoembolization over sorafenib for unresectable hepatocellular carcinoma with portal vein invasion
AASLD LiverLearning®, Hyeki Cho, 144163
Comparisons of metabolically healthy and unhealthy obesity in biopsy-proven nonalcoholic fatty liver disease patients.
AASLD LiverLearning®, ILGUEN PARK, 144419
Hepatitis C virus replication promotes p53 degradation through chaperone-mediated autophagy (CMA).
AASLD LiverLearning®, Yucel Aydin, 144164
Genome-scale Metabolic Models Reveal Metabolic Alterations in a Human Surrogate Model of Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Stephen Hoang, 144420
The FXR/TGR5 dual agonist INT-767 prevents and reverses Western diet-induced NASH and modulates major lipid metabolic pathways in mice.
AASLD LiverLearning®, Xiaoxin Wang, 144421
Gene Network Analysis Reveals a Novel 22-Gene Signature of Carbon Metabolism in Hepatocellular Carcinoma
AASLD LiverLearning®, jinqiang zhang, 144178
Pirfenidone LP activates PPARα and LXRα and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet
AASLD LiverLearning®, José Macías-Barragán, 144434
Liver microRNA hsa-miR-125a-5p exerts an oncosuppressor effect on hepatocellular carcinoma (HCC) regulating the expression of MMP11, c-Raf and SIRT7.
AASLD LiverLearning®, Nicola Coppola, 144179
Vitamin D3 up-regulated protein 1-depentant autophagy and fatty acid oxidation attenuate liver steatosis
AASLD LiverLearning®, HYO JUNG KWON, 144435
Success of Photodynamic Therapy in Palliating Patients With Nonresectable Cholangiocarcinoma: A Meta-Analysis and Systematic Review
AASLD LiverLearning®, Zohair Ahmed, 144180
Angiogenesis in the Pathogenesis of Non-Alcoholic Fatty Liver Diseases (NAFLD)
AASLD LiverLearning®, Savneet Kaur, 144436
Role of Dietary Fatty Acids in Liver Injury Caused by Vinyl Chloride Metabolites in Mice
AASLD LiverLearning®, Lisanne Anders, 144437
Basic Research Workshop: Program Chair
AASLD LiverLearning®, Mario Strazzabosco, 154677
Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma
AASLD LiverLearning®, Kohei Ogawa, 144194
Rapid development of NASH in FLS-ob/ob mice and its application for anti-fibrosis evaluation, -Effects of pioglitazone on liver fibrosis and metabolic parameters-
AASLD LiverLearning®, Tadateru Hamada, 144450
Therapeutic option as an alternative strategy for a solitary (3-5 cm) hepatocellular carcinoma; an analysis of a nationwide cancer registry database
AASLD LiverLearning®, Young-Joo Jin, 144195
involvement of type 4 porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
AASLD LiverLearning®, Takashi Nakahara, 144451
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the T reatment of S mall H epatocellular C arcinoma
AASLD LiverLearning®, Huijun Xu, 144196
Intervention with the CCR2 inhibitor propagermanium attenuates insulin resistance, adipose tissue inflammation and NASH development
AASLD LiverLearning®, Kanita Salic, 144452
The effects of gut microbiota and the flavin mono-oxygenase enzyme 3 (FMO3) on choline bioavailability in nonalcoholic fatty liver disease
AASLD LiverLearning®, Naim Alkhouri, 144453
A Novel Single Daily Fixed Dose Combination of Sofosbuvir400 mg + Ribavirin1000mg + EGCG400 mg is Superior to the Standard of Care as an Anti-Viral and Safer Causing less Hemolysis in Patients with Chronic Hepatitis C
AASLD LiverLearning®, Gamal Shiha, 154955
Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)
AASLD LiverLearning®, Tarek Hassanein, 154956
Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an analysis of multiple real world cohorts totaling >6,500 patients
AASLD LiverLearning®, Vinay Sundaram, 154957
Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
AASLD LiverLearning®, Susan Bersoff-Matcha, 154958
Hepatobiliary Neoplasia SIG: NASH and HCC: Program Chair
AASLD LiverLearning®, Lopa Mishra, 154703
Surgical Management of Recurrent Intrahepatic Cholangiocarcinoma; Predictors, Adjuvant Chemotherapy, and Surgical Therapy for Recurrence: A Multi-Institutional Study by the Kyushu Study Group of Liver Surgery
AASLD LiverLearning®, Yo-ichi Yamashita, 144210
Apg2 is a key determinant of hepatic steatosis by regulating AMPK activity
AASLD LiverLearning®, Hiroshi Ishiba, 144466
Metabolic disorders across hepatocellular carcinoma in Italy.
AASLD LiverLearning®, Filomena Morisco, 144211
The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Kirstine Tølbøl, 144467
Nucleos(t)ide analogues improved survival of CHB-related HCC patients
AASLD LiverLearning®, wang yun, 144212
Activation of autophagy attenuates alcohol-LPS-induced hepatic steatosis and injury through MD2 associated TLR4 signaling
AASLD LiverLearning®, Wenke Feng, 144468
Comparison of Obeticholic Acid and GFT505 (Elafibranor) for Treatment of Non-Alcoholic Steatohepatitis (NASH) in a Human In Vitro Surrogate System
AASLD LiverLearning®, Ryan Feaver, 144469
Spexin, a novel regulator of lipid & carbohydrate metabolism, is a potential therapeutic for obesity, type 2 diabetes mellitus, & non-alcoholic fatty liver disease.
AASLD LiverLearning®, Paul Berk, 154971
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Sheila DeWitt, 154972
Endoscopic duodenal mucosal resurfacing (DMR) improves insulin sensitivity, hepatic transaminase levels and anti-inflammatory markers in type 2 diabetes subjects
AASLD LiverLearning®, Harith Rajagopalan, 154973
The effect of interferon-free therapy on tumor recurrence in HCV patients with treatment history of hepatocellular carcinoma
AASLD LiverLearning®, Yasuhiro Tsuda, 144226
Clinical Characteristics, Management and Outcomes of Patients with Hepatocellular Carcinoma in Africa: Multi-Country Study from the Africa Liver Cancer Consortium.
AASLD LiverLearning®, Ju Dong Yang, 144227
DPP4 Inhibitor Suppressed Warburg-Dickens Pathway and HCC Progression in a Mouse Model of NASH: A Metabolomic Analysis
AASLD LiverLearning®, Takumi Kawaguchi, 144483
Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B
AASLD LiverLearning®, Su Jong Yu, 144228
Iron chelator suppresses hepatocarcinogenesis through mitophagy induction in STAM® mice
AASLD LiverLearning®, Yuhichi Hara, 144484
Roles of CC chemokine receptor 9 in the progression of murine non-alcoholic steatohepatitis
AASLD LiverLearning®, Rei Miyake, 144485
Serum Proteomic Biomarkers of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Diseases in a Newly Established Pig Model
AASLD LiverLearning®, Naohiko Namakura, 144486
Intraductal papillary neoplasm of the bile duct: histological and molecular analysis of 27 patients
AASLD LiverLearning®, Yoshiki Naito, 144242
Education Level and Household Income is Significantly Associated with Disparities in Hepatocellular Carcinoma Stage at Diagnosis and Treatment Received
AASLD LiverLearning®, Johnathan Ha, 144243
ER Stress Regulates Autophagy and Protein Secretion through IBTKα during the Pathogenesis of Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, Jeffrey Willy, 144499
DNA methylation level of non-cancerous liver tissue has potential for being a biomarker of multicentric recurrence of hepatocellular carcinoma
AASLD LiverLearning®, Takuji Torimura, 144244
Macrophage-Specific Deletion of SHP Exacerbates Diet-induced Nonalcoholic steatohepatitis in Mice
AASLD LiverLearning®, Roeland Zoutendijk, 144500
Combination treatment of dipeptidyl peptidase IV inhibitor and angiotensin-II type 1 receptor blocker attenuates progression of nonalcoholic steatohepatitis in rats
AASLD LiverLearning®, Shinya Sato, 144502
Oral pentamidine (VLX103) is an effective treatment for high fat diet-induced NASH in mice
AASLD LiverLearning®, Mark Czaja, 144503
The prognostic impact of TERT promotor mutations and rs2853669 single nucleotide polymorphism combination in hepatocellular carcinoma
AASLD LiverLearning®, Helder Cardoso, 144258
Liver Transplantation for Hepatocellular carcinoma: Results from a Multicenter Cohort from Latin America.
AASLD LiverLearning®, Federico Piñero, 144259
Real-life Adherence to BCLC Therapeutic Algorithm of Hepatocellular carcinoma in a Multicenter cohort from Argentina.
AASLD LiverLearning®, Federico Piñero, 144260
In Hepatocytes, DNA Methylation and Hydroxymethylation Are Altered in Response to Oleic Acid Exposure: A Potential Mechanism for Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 144516
Hepatic Sonic Hedgehog (SHH) Expression Measured by Computer Assisted Morphometry Correlates Histologic Features of Non-Alcoholic Steatohepatitis (NASH) and Circulating Markers of Apoptosis and Cell Injury
AASLD LiverLearning®, Zobair Younossi, 144517
Retinoic acid as a factor in the pathogenesis of NAFLD
AASLD LiverLearning®, Lixin Zhu, 144518
High-Fat Diet Induced Non-Alcoholic Steatohepatitis Impairs Liver Regeneration Post Hepatectomy
AASLD LiverLearning®, S.M.Touhidul Islam, 144519
Higher Mortality Rate after Liver Transplantation in Non-Obese Patients: Is This another indication of the Obesity Paradox?
AASLD LiverLearning®, Elnaz Jafarimehr, 144274
Graft quality matters: KDPI is more predictive of survival than SLK compared with liver transplant alone in a propensity score matched cohort
AASLD LiverLearning®, Colleen Jay, 144275
Disparities associated with out of Region Migration of Liver Transplant Candidates: A Case for Redistricting of UNOS Regions
AASLD LiverLearning®, George Cholankeril, 144276
A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma
AASLD LiverLearning®, Jeroen van Vugt, 144290
Multicenter Study on Down-staging of Hepatocellular Carcinoma for Liver Transplantation: Is Down-staging Failure due to the Tumor or the Long Waiting time?
AASLD LiverLearning®, Neil Mehta, 144291
Combined Lung and Liver Transplantation Offers Superior Outcomes Compared to Lung Transplantation Alone in Cirrhotics with Portal Hypertension Requiring Lung Transplantation
AASLD LiverLearning®, Jamak Modaresi Esfeh, 144292
Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study
AASLD LiverLearning®, Jonathan Stine, 144306
Critical Flicker Frequency predicts progression among stages of cirrhosis
AASLD LiverLearning®, Javier Ampuero, 144307
Acquired protein C deficiency: a major factor in the hypercoagulable state in patients with cirrhosis.
AASLD LiverLearning®, Armand Abergel, 144308
How to define splenomegaly in the diagnosis of liver cirrhosis? : Significance of splenic volume measurement using ultrasonography
AASLD LiverLearning®, sang gyune kim, 144322
Sleep Abnormalities are More Prominent Among Patients with Compensated Cirrhosis with Portosystemic Collaterals
AASLD LiverLearning®, Maya Balakrishnan, 144323
Presence of hepatic encephalopathy, without ascites or variceal bleeding, is associated with worse outcomes after elective abdominal surgery
AASLD LiverLearning®, Ameish Govindarajan, 144324
Availability of contrast-enhanced ultrasonography for the evaluation of partial splenic embolization in cirrhotic patients with hypersplenism
AASLD LiverLearning®, Takashi Matsuda, 144338
The Fatigue of Chronic Liver Disease is Associated with Altered Circadian Rhythm of Cortisol
AASLD LiverLearning®, Michele Tana, 144339
The effect of hepatic arterial buffer response induced by partial splenic embolization on hepatic function in cirrhotic patients by Child-Pugh classification
AASLD LiverLearning®, Ryo Sasaki, 144340
Assessment of nutritional status through bioelectrical impedance is a key determinant of outcome in alcoholic hepatitis: a prospective study
AASLD LiverLearning®, Laurent Spahr, 144098
COP II trafficking promotes hepatitis C virus entry through claudin-1
AASLD LiverLearning®, Peiqi Yin, 144354
Alcohol Misuse is Associated with Intestinal Mucosal Dysbiosis and Stool Metabolomic Alterations In Human Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144099
Selenoprotein P, a liver-derived secretory protein, regulates RIG-I-mediated innate immunity in hepatocytes
AASLD LiverLearning®, Kazuhisa Murai, 144355
Hepatic Overexpression of Splicing Regulator Slu7 Ameliorates Alcoholic Steatosis in Mice via Modification of SIRT1 Alternative Splicing
AASLD LiverLearning®, Min You, 144100
T Cell Functionality in Chronic Hepatitis C Patients Treated With the Anti-miR-122 RG-101
AASLD LiverLearning®, Femke Stelma, 144356
The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from ASTRAL-5
AASLD LiverLearning®, Zobair Younossi, 144369
The chemical chaperone 4-phenylbutyric acid prevents ethanol-induced liver injury in diabetic KK-Ay mice
AASLD LiverLearning®, Maiko Suzuki, 144114
A liver-derived secretory protein, LECT2, enhances the innate immune response and suppresses HCV replication
AASLD LiverLearning®, Takayoshi Shirasaki, 144370
Acute-on-chronic alcohol exposure using the ‘NIAAA model’ concomitantly damages the liver and lung
AASLD LiverLearning®, Lauren Poole, 144115
Decreased NKG2D on Natural Killer Cells After IFN-free DAAs Correlates to Early HCC Emergence in Chronic Hepatitis C
AASLD LiverLearning®, Po-Sung Chu, 144371
Proteome Dynamics reveals that High Density Lipoprotein Dysfunction in Nonalcoholic Steatohepatitis is related to Increased Degradation of HDL proteins involved in Reverse Cholesterol Transport.
AASLD LiverLearning®, Takhar Kasumov, 144116
The mechanism of lncRNA IFI6 regulation of HCV infection
AASLD LiverLearning®, Xiao Liu, 144372